The Mexico DNA Diagnostics Market was valued at $88.9 Million in 2024 and projected to reach to $135.2 Million by 2029, representing a compound annual growth rate of 8.7%. Mexico's DNA diagnostics market is positioned for sustained growth through 2029, supported by demographic shifts, rising disposable incomes, and increasing prevalence of chronic diseases requiring genetic screening.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Mexico's DNA diagnostics market is valued at $88.9 million in 2024, with projections reaching $135.2 million by 2029, representing a robust 8.7% CAGR driven by increasing genetic testing adoption.
Mexico's growing middle class and enhanced healthcare awareness are accelerating demand for personalized medicine and preventive genetic diagnostics across urban and semi-urban populations.
Both public healthcare institutions and private medical facilities in Mexico are increasingly integrating DNA diagnostic services, expanding accessibility and market penetration across diverse patient demographics.
Enhanced infrastructure and improved access to diagnostic technologies in Mexico are enabling broader adoption of genetic testing, particularly in oncology, pharmacogenomics, and hereditary disease screening.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | HPV (Type) |
| Forecast Period | 2024-2029 |
| Growth Rate | CAGR of 9.7% from 2024 to 2029 |
| Largest Segment | BLOOD, PLASMA, AND SERUM (Specimen) |
| Market Size Base Year (Billions) | ~USD 13.34 (2024) |
| Revenue Forecast (Billions) | ~USD 21.2 (2029) |
| Segments Covered | Offering, Technology, Specimen, Application, Type, End User |
6 segment dimensions are covered across the global market.
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| DIAGNOSTIC LABORATORIES | 69.2 | 74.5 | 80.8 | 87.9 | 96 | 105.2 | 115.6 | 127.3 | 9.5 |
| HOSPITALS & CLINICS | 33.8 | 35.8 | 38.1 | 40.8 | 43.7 | 46.9 | 50.5 | 54.5 | 7.4 |
| OTHER END USERS | 19.6 | 20.2 | 21.1 | 22 | 23 | 24.2 | 25.5 | 27 | 5.1 |
| TOTAL | 122.6 | 130.5 | 140 | 150.7 | 162.7 | 176.3 | 191.6 | 208.8 | 8.3 |
Mexico's DNA diagnostics market was valued at $88.9 million in 2024 and is expected to reach $135.2 million by 2029.
Mexico's DNA diagnostics market is growing at a compound annual growth rate (CAGR) of 8.7% from 2024 to 2029.
Growth in Mexico is driven by rising healthcare awareness, improved diagnostic infrastructure, increasing adoption of personalized medicine, and expanding private healthcare sector investment in genetic testing capabilities.
Mexico's DNA diagnostics market is seeing strong activity in oncology screening, infectious disease testing, and hereditary condition diagnostics across both public and private healthcare providers.
Mexico represents a significant portion of Latin America's DNA diagnostics market due to its large population, developed healthcare infrastructure, and strategic position as a regional healthcare hub.
To determine the current size of the DNA diagnostics market, this study engaged in four main activities. A comprehensive study was conducted using secondary research methods to gather data about the market, its parent market, and its peer markets. The next stage involved conducting primary research to confirm these conclusions, assumptions, and sizing with industry experts throughout the value chain. A combination of top-down and bottom-up methods was used to assess the overall market size. The market sizes of segments and subsegments were then estimated using data triangulation techniques and market breakdown.
The four steps involved in estimating the market size are
Within the secondary data collection process, a range of secondary sources were reviewed so as to identify and gather data for this study, including regulatory bodies, databases (like D&B Hoovers, Bloomberg Business, and Factiva), white papers, certified publications, articles by well-known authors, annual reports, press releases, and investor presentations of companies.
During the primary research phase, a comprehensive approach was adopted, involving interviews with a diverse array of sources from both the supply and demand sides. These interviews aimed to gather qualitative and quantitative data essential for compiling this report. Primary sources primarily comprised industry experts spanning core and related sectors, as well as favored suppliers, manufacturers, distributors, service providers, technology innovators, and entities associated with all facets of this industry's value chain. In-depth interviews were meticulously conducted with a range of primary respondents, including key industry stakeholders, subject-matter authorities, C-level executives representing pivotal market players, and industry advisors. The objective was to obtain and authenticate critical qualitative and quantitative insights and to evaluate future potentialities comprehensively.
A breakdown of the primary respondents is provided below:

Note 1: Others include sales, marketing, and product managers.
Note 2: Tiers of companies are defined based on their total revenue. As of 2023, Tier 1 = >USD 5 billion, Tier 2 = USD 500 million to USD 5 billion, and Tier 3 = <USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
|
COMPANY NAME |
DESIGNATION |
|
Roche Diagnostics Ltd. |
Area Sales Manager |
|
Danaher Corporation |
General Manger |
|
Thermo Fisher Scientific Inc. |
Consultant |
All major product providers offering various products and services were identified at the global/regional level. Revenue mapping was done for the major players and was extrapolated to arrive at the global market value of each type of segment. The market value of the DNA diagnostics market was also split into various segments and subsegments at the region and country level based on:

To know about the assumptions considered for the study, Request for Free Sample Report

After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
DNA diagnostic tests detect and analyze variations in the sequence, structure, or expression of deoxyribonucleic acid (DNA) to diagnose diseases or medical conditions. This includes identifying indications caused by specific pathogens or determining genetic carrier status.
DNA diagnostic techniques can detect numerous diseases, such as cancer, viral diseases, and myogenic disorders. They are also employed in prenatal diagnostics and clinical diagnostic confirmation.
With the given market data, MarketsandMarkets offers customizations to meet the company’s needs. The following customization options are available for the report:
Further breakdown of the DNA diagnostics market into specific countries/regions in Europe, Asia Pacific, Latin America, Middle East & Africa, and GCC Countries.
Detailed analysis and profiling of additional market players (up to Five), inclusive of:
Note: Some companies are privately owned, and their revenues are unavailable in the public domain. Hence, revenues for privately owned companies will not be included in their profile. In addition, company developments that are not reported in the public domain will not be included.
Full forecast, segment splits, and company analysis for all DNA Diagnostics Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report